

Armored RNA Quanti[®] SARS-CoV-2 Panel

Armored Controls have been utilized in FDA-approved assays for last 20+ years and continue to serve as an important tool in the rapidly evolving space of molecular diagnostics.

In response to the worldwide outbreak of COVID-19, Asuragen has developed a novel Armored RNA control panel that targets the SARS-CoV-2 viral nucleocapsid (N), envelope (E), RNA-dependent RNA polymerase (RdRp), Open Reading Frame sequence (ORF1ab), and human RNase P regions. This all-in-one panel aligns with the CDC and WHO recommended regions for testing providing a stable, reliable, and safe way to rapidly test for the presence of the novel Coronavirus with confidence.

Each control encodes *in vitro* transcribed RNA encapsulated in a protective protein coat to create a virus-like particle resistant to nuclease degradation. This allows the product to be used as RNA extraction control, process quality control, or positive diagnostic reference controls. From feasibility to clinical use, this robust and versatile control is beneficial across all sectors of the research and diagnostic spectrum.

Armored RNA Quanti[®]
**THE GOLD STANDARD
FOR MOLECULAR
QUALITY CONTROL**

REDUCED COMPLEXITY

- Available as standalone catalog item
- High-quality solution to monitor extraction and process efficiency
- Compatible with a wide range of RNA-based clinical assays
- Non-infectious, synthetic constructs simplify shipping and storage

OPTIMIZED WORKFLOW

- Deployable as extractable, exogenous internal positive control
- Tailored sequences specific to SARS-CoV-2 and RNase P
- Degradation resistant in majority of biological matrices
- Multiple volume and manufacturing options available
- Available as cGMP or development lot in a range of fill volumes


QUALITY PERFORMANCE

- Concentration determined using National Institute of Standards (NIST) traceable standard
- Highly standardized, quality controlled manufacturing ensures reliability and consistency between lots
- Manufactured in a cell-free system

Armored RNA Quant® SARS-CoV-2 Panel

- Concentration: 1×10^{11} copies/mL and can be customized
- Buffer Composition: TSM III (10 mM Tris, 100 nM NaCl, 1 mM MgCl₂, 0.1% Gelatin, 0.3% Microcide III, pH 7.0)
- Storage at -15 to -30°C

Packaged SARS-CoV-2 Panel detailed sequences available on [page 3](#)



ORDERING INFORMATION

Part Number	Product Description	Volume	Concentration
52030	Armored RNA Quant SARS-CoV-2	0.25mL	1×10^{11} cp/mL
52031	Armored RNA Quant RNase P	0.25mL	1×10^{11} cp/mL
52036	Armored RNA Quant SARS-CoV-2 Panel	0.25mL	1×10^{11} cp/mL

For more information about Armored RNA Quant® SARS-CoV-2 Panel | armored@asuragen.com



Asuragen, Inc.
 2150 Woodward Street, Suite 100
 Austin TX 78744
www.asuragen.com

Armored RNA Quant® is a technology developed jointly by Ambion, Inc. and Cenetron Diagnostics, LLC (US patents #5,677,124, #5,919,625, #5,939,262, #6,214,982, and #6,399,307). Armored RNA Quant® is a registered trademark of Ambion and Cenetron Diagnostics. For Research Use Only. Not For Use in Diagnostic Procedures.

SARS-CoV-2 Panel* detailed sequences

RdRp

TGTAGAAAACCCCTCACCTTATGGGTTGGGATTATCCTAAATGTGATAGAGCCATGCCTAACATGCTTAGAATTATG
GCCCACTTGTCTTGCTCGCAAACATACAACGTGTTGTAGCTTGTACACCCGTTTCTATAGATTAGCTAATGAGTGTG
CTCAAGTATTGAGTGAATGGTCATGTGTGGCGGTTCACTATATGTTAAACCAGGTGGAACCTCATCAGGAGAT
GCCACAACCTGCTTATGCTAATAGTGTGTTTAAACATTTGTCAAGCTGTCACGGCCAATGTTAATGCACTTTTATCTACT
GATGGTAAACAAAATTGCCGATAAGTATGTCCGCAATTTACAACACAGACTTTATGAGTGTCTTATAGAAAATAGAG
ATGTTGACACAGACTTTGTGAATGAGTTTTACGCATATTTGCGTAAACATTTCTCAATGATGATACTCTCTGACGAT
GCTGTTGTGTGTTTCAATAGCACTTATGCA

E

GTTGAACATGTTACCTTCTTCATCTACAATAAAATTGTTGATGAGCCTGAAGAACATGTCCAAATTCACACAATCGA
CGGTTTCATCCGGAGTTGTTAATCCAGTAATGGAACCAATTTATGATGAACCGACGACGACTACTAGCGTGCCTTTG
TAAGCACAAGCTGATGAGTACGAACCTTGTACTCATTGTTTTCGGAAGAGACAGGTACGTTAATAGTTAATAGCG
TACTTCTTTTTCTTGCTTTCTGTTGTTTCTGCTAGTTACACTAGCCATCCTTACTGCGCTTCGATTGTGTGCGTACTG
CTGCAATATTGTTAACGTGAGTCTTGAAAACCTTCTTTTTACGTTTACTCTCGTGTTAAAAATCTGAATTTCTTCTAG
AGTTCTGATCTTCTGGTCTAAACGAACATAAATATTATATTAGTTTTTCTGTTTGGAACTTTAATTTTAGCCATGGCA
GATTCCAACGGTACTATTACCGTTGA

N

GAACAACTAAAATGTCTGATAATGGACCCCAAAATCAGCGAAATGCACCCCGCATTACGTTTGGTGGACCCCTCAG
ATTCAACTGGCAGTAACCAGAATGGAGAACCGCAGTGGGGCGCGATCAAACAACGTCGGCCCAAGGTTTACCCA
ATAATACTGCGTCTTGGTTCACCGCTCTCACTCAACATGGCAAGGAAGACCTTAAATTCCTCGAGGACAAGGCGT
TCCAATTAACACCAATAGCAGTCCAGATGACCAAATTGGCTACTACCGAAGAGCTACCAGACGAATTCGTGGTGGT
GACGGTAAAATGAAAGATCTCAGTCCAAGATGGTATTTCTACTACCTAGGAACTGGGCCAGAAGCTGGACTTCCCT
ATGGTGCTAACAAAGACGGCATCATATGGGTTGCAACTGAGGGAGCCTTGAATACACCAAAAAGATCACATTGGCA
CCCGCAATCCTGCTAACAAATGCTGCAATCGTGCTACAACCTCCTCAAGGAACAACATTGCCAAAAGGCTTCTACGC
AGAAGGGAGCAGAGGCGGCAGTCAAGCCTCTTCTCGTTCCTCATCACGTAGTCGCAACAGTTCAAGAAATTCAAC
TCCAGGCAGCAGTAGGGGAACCTTCTCTGCTAGAATGGCTGGCAATGGCGGTGATGCTGCTCTTGCTTTGCTGCT
GCTTGACAGATTGAACCAGCTTGAGAGCAAAATGTCTGGTAAAGGCCAACAACAACAAGGCCAAACTGTCACTAA
GAAATCTGCTGCTGAGGCTTCTAAGAAGCCTCGGCAAAAACGTACTGCCACTAAAGCATACAATGTAACACAAGCT
TTCGGCAGACGTGGTCCAGAACAACCCAAAGGAAATTTGGGGACCAGGAACATAATCAGACAAGGAACTGATTAC
AAACATTGGCCGCAATTCACAATTTGCCCCAGCGCTTACCGTTCCTCGGAATGTCGCGCATTGGCATGGAAG
TCACACCTTCGGGAACGTG

ORF

TGGTGCATCGTGTGTTGTCTGTACTGCCGTTGCCACATAGATCATCAAATCCTAAAGGATTTTGTGACTTAAAAGGTA
AGTATGTACAAATACCTACAACCTTGTGCTAATGACCCTGTGGGTTTTACACTTAAAAACACAGTCTGTACCGTCTGC
GGTATGTGGAAGGTTATGGCTGTAGTTGTGATCAACTCCGCGAACCCATGCTTCAGTCAGCTGATGCACAATCGT
TTTTAAACGGGTTTGGCGGTGTAAGTGCAGCCGCTTACACCGTGCGGCACAGGCCTAGTACTGATGTCGTATAC
AGGGCTTTTGCATCTACAATGATAAAGTAGCTGGTTTTGCTAA

RNAse P

GAATTCGGCAGGAGGTGGGACTTCAGCATGGCGGTGTTTGCAGATTTGGACCTGCGAGCGGGTTCTGACCTGAAG
GCTCTGCGCGGACTTGTGGAGACAGCCGCTCACCTTGCTATTTCAGTTGTTGCTATCAATCATATCGTT

*For Research Use Only. Not For Use in Diagnostic Procedures.

